Indirect Costs in Ambulatory Patients with HIV/AIDS in Spain: A Pilot Study

PharmacoEconomics

Volumn 21, Issue 15, 2003, Pages 1113-1121

  Oliva, Juan ^a,b,d   Roa, César ^c   Del Llano, Juan ^b  

^a UNIVERSIDAD CARLOS III DE MADRID   (Spain)

^b Fundacion Gaspar Casal   (Spain)

^c UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^d Department of Economics ^*  (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AMBULATORY CARE; ARTICLE; CLINICAL ARTICLE; COST; EDUCATION; EMPLOYMENT; FEMALE; GENDER; HOUSEHOLD; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCOME; MALE; PRIORITY JOURNAL; QUALITY OF LIFE; SALARY; SPAIN;

COST OF ILLNESS; DRUG THERAPY, COMBINATION; EMPLOYMENT; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INCOME; MALE; MODELS, ECONOMETRIC; PILOT PROJECTS; QUALITY OF LIFE; SPAIN;

EID: 0142217259     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200321150-00005     Document Type: Article

References (29)

1. Fauci AS. The AIDS Epidemic: considerations for the 21st century. N Engl J Med 1999; 341: 1046-50
2. Casabona J. Sida o infección por VIH? Implicaciones sanitarias. Med Clin (Barc) 1999; 112: 335-6
3. Ojo K, Delaney M. Economic and demographic consequences of AIDS in Namibia: rapid assessment of the costs. Int J Health Plann Manage 1997; 12: 315-26
4. Cabasés Hita JM. Cuánto nos cuesta el Sida? Med Clin (Barc) 1995; 104: 573-5
5. Beck EJ, Miners AH, Tolley K. The cost of HIV treatment and care: a global review. Pharmacoeconomics 2001 Jan; 19 (1): 13-39
6. HIV/AIDS. A threat to decent work, productivity and development (2000). Document for discussion at the Special High-Level Meeting on HIV/AIDS and the World of Work; 2000 Jun 8; Geneva. ILO (International Labour Organization). SafeWork - Programme on HIV/AIDS. Available from URL: www.ilo.org/public/ english/protection/trav/aids/publ/ threatdecentworkeng.pdf [Accessed 2003 Aug]
7. Spanish Ministry of Health and Consumer Affairs. Epidemiología. Available from URL: http://www.msc.es/sida/epidemiologia/home.htm [Accessed 2003 Aug 6]
8. Castilla J, De la Fuente L. Evolución del número de personas infectadas por el virus de la inmunodeficiencia humana y de los casos de sida en España: 1980-1998. Med Clin (Barc) 2000; 115: 85-9
9. Encuesta hospitalaria sobre la utilización de recursos y características de los pacientes VIH/sida. Madrid: Ministerio de Sanidad y Consumo, 1998 Nov
10. Antonanzas VF, Anton F, Juarez C, et al. Cálculos de los costes del sida en España mediante técnicas de simulación. Med Clin (Barc) 1995; 104: 568-72
11. Mompo C, Abbas I, Santin M, et al. La utilización de recursos sanitarios en pacientes infectados por el VIH: creación de una base de datos y obtención de resultados de costes. Gac Sanit 2000 Enero/febrero; 14 (1): 39-47
12. Pinto JL, Lopez Lavid C, Badia X, et al. Análisis coste efectividad del tratamiento antirretroviral de gran actividad en pacientes infectados por el VIH asintomáticos. Med Clin (Barc) 2000, 114 Suppl. 3: 62-7
13. Gebo KA, Chaisson RE, Folkemer JG, et al. Costs of HIV medical care in the era of highly active antiretroviral therapy. AIDS 1999 May 28; 13 (8): 963-9
14. Kahn JG, Marseille E. Fighting global AIDS: the value of cost-effectiveness analysis. AIDS 2000 Nov 10; 14 (16): 2609-10
15. Lapins DL, Urdaneta ME, Barren J, et al. Costs of care for HIV infection in a managed care population from 1995 to 1997. Am J Manag Care 2000 Sep; 6 (9): 973-81
16. Wallace MR, Tasker SA, Shinohara YT, et al. The changing economics of HIV care. AIDS Patient Care STDS 2001 Jan; 15 (1): 25-9
17. Sendi P, Palmer AJ, Gafni A, et al. Highly active antiretroviral therapy: pharmacoeconomic issues in the management of HIV infection. Pharmacoeconomics 2001; 19 (7): 709-13
18. Oliva J. La valoración de los costes indirectos en la evaluación sanitaria. Med Clin (Barc) 2000, 114 Suppl. 3: 15-21
19. Mullins CD, Whitelaw G, Cooke JL, et al. Indirect cost of HIV infection in England. Clin Ther 2000 Nov; 22 (11): 1333-45
20. Sendi PP, Bücher HC, Harr T, et al. Cost effectiveness of highly active antiretroviral therapy in HIV-infected patients. AIDS 1999; 13: 1115-22
21. Freedberg KA, Losina E, Weinstein MC, et al. The cost effectiveness of combination antiretroviral therapy for HIV disease. N Engl J Med 2001; 344 (11): 824-31
22. Johannesson M. The willingness to pay for health changes, the human-capital approach and the external costs. Health Policy 1996; 36: 232-44
23. Posnett J, Jan S. Indirect cost in economic evaluation: the opportunity cost of unpaid inputs. Health Econ 1996; 5: 13-23
24. Pinto JL, Puig-Junoy J. El coste de oportunidad del tiempo remunerado en la produccion [working paper]. Madrid: Fundación BBVA, 2001
25. Liljas B. How to calculate indirect costs in economic evaluation. Pharmacoeconomics 1998; 13 (1): 1-7
26. Palella Jr FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338 (13): 853-60
27. Freedberg KA, Losina E, Weinstein MC, et al. The cost effectiveness of combination antiretroviral therapy for HIV disease. N Engl J Med 2001; 344 (11): 824-31
28. Canadian Coordinating Office for Health Technology Assessment. Guidelines for economic evaluation of pharmaceutical: Canada. 2nd ed. Ottawa (ON): Canadian Office for Health Technology Assessment (COOHTA), 1997
29. Johannesson M, Jönsson B, Karlsson G. Outcome measurement in economic evaluation. Health Econ 1996; 5: 279-96